Literature DB >> 26859079

The possible perils of targeted therapy.

U Duffner1,2, A Abdel-Mageed1,2, J Younge1, C Tornga1, K Scott3, J Staddon3, K Elliott3, J Stumph2,4, P Kidd2,4.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26859079     DOI： 10.1038/leu.2016.18

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  Acute monocytic leukaemia originating from MLL-MLLT3-positive pre-B cells.

Authors:  Caroline Hutter; Andishe Attarbaschi; Susanna Fischer; Claus Meyer; Michael Dworzak; Margit König; Rolf Marschalek; Georg Mann; Oskar A Haas; E Renate Panzer-Grümayer
Journal:  Br J Haematol       Date:  2010-05-20       Impact factor: 6.998

2.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors:  Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

Review 3.  MLL leukemia and future treatment strategies.

Authors:  Rolf Marschalek
Journal:  Arch Pharm (Weinheim)       Date:  2015-03-04       Impact factor: 3.751

4.  Bipotential B-macrophage progenitors are present in adult bone marrow.

Authors:  E Montecino-Rodriguez; H Leathers; K Dorshkind
Journal:  Nat Immunol       Date:  2001-01       Impact factor: 25.606

5.  Lineage switch in childhood acute leukemia: an unusual event with poor outcome.

Authors:  Jorge G Rossi; Andrea R Bernasconi; Cristina N Alonso; Patricia L Rubio; Marta S Gallego; Carolina A Carrara; Myriam R Guitter; Silvia Eandi Eberle; Mariela Cocce; Pedro A Zubizarreta; María S Felice
Journal:  Am J Hematol       Date:  2012-06-08       Impact factor: 10.047

6.  Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.

Authors:  Max S Topp; Nicola Gökbuget; Gerhard Zugmaier; Petra Klappers; Matthias Stelljes; Svenja Neumann; Andreas Viardot; Reinhard Marks; Helmut Diedrich; Christoph Faul; Albrecht Reichle; Heinz-August Horst; Monika Brüggemann; Dorothea Wessiepe; Chris Holland; Shilpa Alekar; Noemi Mergen; Hermann Einsele; Dieter Hoelzer; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

Review 7.  Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.

Authors:  Gerhard Zugmaier; Matthias Klinger; Margit Schmidt; Marion Subklewe
Journal:  Mol Immunol       Date:  2015-04-13       Impact factor: 4.407

Review 8.  Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?

Authors:  Emmanuelle Passegué; Catriona H M Jamieson; Laurie E Ailles; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

9.  CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage.

Authors:  L Slamova; J Starkova; E Fronkova; M Zaliova; L Reznickova; F W van Delft; E Vodickova; J Volejnikova; Z Zemanova; K Polgarova; G Cario; M Figueroa; T Kalina; K Fiser; J P Bourquin; B Bornhauser; M Dworzak; J Zuna; J Trka; J Stary; O Hrusak; E Mejstrikova
Journal:  Leukemia       Date:  2013-11-25       Impact factor: 11.528
  9 in total
  5 in total

1.  Blinatumomab for HLA loss relapse after haploidentical hematopoietic stem cell transplantation.

Authors:  Hengwei Wu; Zhen Cai; Jimin Shi; Yi Luo; He Huang; Yanmin Zhao
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

2.  Antigen Loss Variants: Catching Hold of Escaping Foes.

Authors:  Maulik Vyas; Rolf Müller; Elke Pogge von Strandmann
Journal:  Front Immunol       Date:  2017-02-24       Impact factor: 7.561

3.  Enhancing adoptive CD8 T cell therapy by systemic delivery of tumor associated antigens.

Authors:  Ditte E Jæhger; Mie L Hübbe; Martin K Kræmer; Gael Clergeaud; André V Olsen; Camilla Stavnsbjerg; Mette N Wiinholt; Andreas Kjær; Jonas R Henriksen; Anders E Hansen; Thomas L Andresen
Journal:  Sci Rep       Date:  2021-10-05       Impact factor: 4.379

4.  Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.

Authors:  C L Haddox; A A Mangaonkar; D Chen; M Shi; R He; J L Oliveira; M R Litzow; A Al-Kali; W J Hogan; M A Elliott
Journal:  Blood Cancer J       Date:  2017-09-15       Impact factor: 11.037

5.  Immunotherapy- (Blinatumomab-) Related Lineage Switch of KMT2A/AFF1 Rearranged B-Lymphoblastic Leukemia into Acute Myeloid Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute Leukemia.

Authors:  Rui R He; Zacharia Nayer; Matthew Hogan; Raymund S Cuevo; Kimberly Woodward; David Heyer; Christine A Curtis; Jess F Peterson
Journal:  Case Rep Hematol       Date:  2019-12-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.